SCHEMBL4773053

SCHEMBL4773053

O=S(=O)(CCNc1cc(-c2cccnc2)nc(-c2ccccn2)n1)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 3/20 0.44
PIK3CA P42336 7/20 0.43
PIK3CB P42338 3/20 0.43
PIK3CG P48736 3/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
HIF1A Q16665 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 2/20 0.41
NPY5R Q15761 1/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM6A O15550 2/20 0.40
KDM5A P29375 2/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239971 0.81 SMN1; SMN2 (0.53) MTORPIK3CACYP3A4CYP2C9LMNA
SCHEMBL4773622 0.81 CYP2A6 (0.46) CYP3A4CYP2C9ALDH1A1SMN1; SMN2HIF1A
SCHEMBL4769045 0.78 HDAC1 (0.48) CYP3A4CYP2C9LMNAHIF1AKDM4E
SCHEMBL4775347 0.78 ALDH1A1 (0.51) CYP3A4CYP2C9LMNAALDH1A1SMN1; SMN2
SCHEMBL2241291 0.77 KMT2A (0.46) CYP3A4CYP2C9LMNAALDH1A1SMN1; SMN2
SCHEMBL2241354 0.77 PIK3CA (0.51) MTORPIK3CAPIK3CBPIK3CGCYP3A4
SCHEMBL4774987 0.76 ADORA2A (0.46) CYP3A4CYP2C9HIF1AKDM4EKDM6A
SCHEMBL11968288 0.75 CLK4 (0.45) CYP3A4CYP2C9LMNAALDH1A1SMN1; SMN2
SCHEMBL2238098 0.75 PTGDR (0.53) PIK3CAPIK3CBPIK3CGCYP3A4CYP2C9
SCHEMBL2240945 0.75 GBA1 (0.54) PIK3CAPIK3CBPIK3CGCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed